子宫平滑肌瘤的治疗药物研究进展

doi:10.19803/j.1672-8629.2022.06.24

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (6): 465-468.
DOI: 10.19803/j.1672-8629.2022.06.24

• 综述 • 下一篇

子宫平滑肌瘤的治疗药物研究进展

余娅¹, 彭昌盛^1,2Δ, 崔陶^1,*

¹四川大学华西第二医院妇产科,出生缺陷与相关妇儿疾病教育部重点实验室,四川成都 610041;
²成都市妇女儿童中心医院妇产科,四川成都 610091

收稿日期:2021-12-24 出版日期:2022-06-15 发布日期:2022-06-13
通讯作者: ^* 崔陶,女,博士·硕导,副主任医师,妇产科学。E-mail: cuitao8012@163.com
作者简介:余娅,女,硕士,医师,妇产科学。^Δ为并列第一作者。
基金资助:
国家重点研发计划（2021YFC2009100）; 国家重点研发计划（2020YFC2005600）; 四川省科技厅重点研发项目（2020YFS0206）

Review of drugs on uterine leiomyomas

YU Ya¹, PENG Changsheng^1,2Δ, CUI Tao^1,*

¹Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu Sichuan 610041, China;
²Department of Gynecology and Obstetrics, Chengdu Women's and Children's Central Hospital, Chengdu Sichuan 610091, China

Received:2021-12-24 Online:2022-06-15 Published:2022-06-13

摘要/Abstract

摘要： 子宫平滑肌瘤是妇科最常见的良性肿瘤之一。目前对子宫肌瘤唯一的治愈方式是手术治疗,手术治疗包括子宫肌瘤切除术、全子宫切除术以及次全子宫切除术。手术不可避免地降低了生育能力,并增加了妊娠及妊娠后的产科风险。此外,由于部分子宫肌瘤可能病情稳定或在绝经后萎缩、变小,使得部分患者尤其是有生育需求的患者更倾向于非手术治疗。本文概述了目前临床上治疗子宫平滑肌瘤的常用药物及实验研究中突显出可能具有治疗希望的药物治疗方案,以期对临床治疗工作提供参考。

关键词: 子宫平滑肌瘤, 药物治疗, 醋酸乌利司他

Abstract: Uterine leiomyomas (fibroids) is one of the most common gynecological tumors. At present, the most effective cure method for uterine fibroids is surgery. Surgical approach includes hysteromyomectomy, total hysterectomy and subtotal hysterectomy. Surgery inevitably reduces fertility and increases the obstetrical risks. In addition, because some uterine fibroids may shrink and become smaller after menopause, which makes some patients with childbearing aspiration choosing non-surgical treatments. This article summarizes the currently commonly used drugs in clinical practice and treatments that may be promising in clinical application.

Key words: uterine leiomyomas (fibroids), drug therapy, ulipristal acetate

中图分类号:

余娅, 彭昌盛, 崔陶. 子宫平滑肌瘤的治疗药物研究进展[J]. 中国药物警戒, 2022, 19(6): 465-468.

YU Ya, PENG Changsheng, CUI Tao. Review of drugs on uterine leiomyomas[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 465-468.

参考文献

[1] WISE L, PALMER J, STEWART E, et al.Age-specific incidence rates for self-reported uterine leiomyomata in the black women's health study[J]. Obstetrics and Gynecology, 2005, 105(3): 563-568.
[2] MURJI A, WHITAKER L, CHOW T, et al. Selective progesterone receptor modulators (SPRMs) for uterine fibroids[J]. The Cochrane Database of Systematic Reviews, 2017, 4(4): CD010770.
[3] MCWILLIAMS M, CHENNATHUKUZHI V.Recent advances in uterine fibroid etiology[J]. Seminars in Reproductive Medicine, 2017, 35(2): 181-189.
[4] EDWARDS T, GIRI A, HELLWEGE J, et al.A trans-ethnic genome-wide association study of uterine fibroids[J]. Frontiers in Genetics, 2019,10:511.
[5] STEWART E, COOKSON C, GANDOLFO R, et al.Epidemiology of uterine fibroids: a systematic review[J]. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124(10): 1501-1512.
[6] FAUSTINO F, MARTINHO M, REIS J, et al.Update on medical treat-ment of uterine fibroids[J]. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2017, 216: 61-68.
[7] LETHABY A, VOLLENHOVEN B, SOWTER M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids[J]. The Cochrane Database of Systematic Reviews, 2001(2): CD000547.
[8] LETHABY A, VOLLENHOVEN B, SOWTER M.Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review[J]. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109(10): 1097-1108.
[9] CODDINGTON C, COLLINS R, SHAWKER T, et al.Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri[J]. Fertility and Sterility, 1986,45(5):624-629.
[10] BRITTEN J, MALIK M, LEVY G, et al.Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production[J]. Fertility and Ssterility, 2012, 98(5): 1299-1307.
[11] SURREY E, HORNSTEIN M.Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up[J]. Obstetrics and Gynecology, 2002, 99(5 Pt 1): 709-719.
[12] DETTI L, UHLMANN R, ZHANG J, et al.Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice[J]. Fertility and Sterility, 2014, 101(4): 1157-1164.
[13] GEORGOPOULOS N, ARMENI A, STAMOU M, et al.Gonadotropin-releasing hormone (GnRH) deficiency under treatment: psychological and sexual functioning impacts[J]. Hormones (Athens, Greece), 2018, 17(3): 383-390.
[14] TOFTAGER M, SYLVEST R, SCHMIDT L, et al.Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols[J]. Fertility and Sterility, 2018, 109(1): 154-164.
[15] MORONI R, MARTINS W, FERRIANI R, et al. Add-back therapy with GnRH analogues for uterine fibroids[J]. The Cochrane Database of Systematic Reviews, 2015(3): CD010854.
[16] ARCHER D, STEWART E, JAIN R, et al.Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study[J]. Fertility and Sterility, 2017, 108(1): 152-160, e154.
[17] BARRA F, VITALE S, SECA M, et al.The potential role of elagolix for treating uterine bleeding associated to uterine myomas[J]. Expert Opinion on Pharmacotherapy, 2020, 21(12): 1419-1430.
[18] OSUGA Y, SEKI Y, TANIMOTO M, et al.Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endome-triosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study[J]. Fertility and Sterility, 2021, 115(2): 397-405.
[19] ROCCA M, PALUMBO A, LICO D, et al.Relugolix for the treatment of uterine fibroids[J]. Expert Opinion on Pharmacotherapy, 2020, 21(14): 1667-1674.
[20] MACLEAN D, SHI H, FAESSEL H, et al.Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males[J]. The Journal of Clinical Endocrinology and Metabolism, 2015, 100(12): 4579-4587.
[21] OSUGA Y, ENYA K, KUDOU K, et al.Oral Gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial[J]. Obstetrics and Gynecology, 2019, 133(3): 423-433.
[22] POHL O, MARCHAND L, FAWKES N, et al.Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109[J]. The Journal of Clinical Endocrinology and Metabolism, 2018, 103(2): 497-504.
[23] SHOZU M, MURAKAMI K, INOUE M.Aromatase and leiomyoma of the uterus[J]. Seminars in Reproductive Medicine, 2004, 22(1): 51-60.
[24] ISHIKAWA H, REIERSTAD S, DEMURA M, et al.High aromatase expression in uterine leiomyoma tissues of African-American women[J]. The Journal of Clinical Endocrinology and Metabolism, 2009, 94(5): 1752-1756.
[25] SUMITANI H, SHOZU M, SEGAWA T, et al.In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism[J]. Endocrinology, 2000, 141(10): 3852-3861.
[26] HADJI P, BODY J, AAPRO M, et al.Practical guidance for the management of aromatase inhibitor-associated bone loss[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2008, 19(8): 1407-1416.

子宫平滑肌瘤的治疗药物研究进展

Review of drugs on uterine leiomyomas

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

[1]	原小陇, 万齐华, 陶东红, 祁浩, 王爱霞. 1例甲氨蝶呤片严重中毒患者的药学监护[J]. 中国药物警戒, 2022, 19(8): 924-928.
[2]	卢亚男, 白瑞雪, 杨跃辉. 药物警戒在妊娠期药物治疗中的应用现状及建议[J]. 中国药物警戒, 2022, 19(3): 279-282.
[3]	孙雪林, 胡欣, 张亚同. 熊去氧胆酸的临床应用进展[J]. 中国药物警戒, 2022, 19(10): 1149-1153.
[4]	褚燕琦, 王之舟, 沈江华, 张淼, 张青霞, 曾艳, 闫素英. 基于《中国万古霉素治疗药物监测指南》对我院万古霉素药物治疗监测现状评价研究[J]. 中国药物警戒, 2017, 14(7): 435-438.
[5]	钱晓路, 孙蓉. 基于分子水平的AD治疗药物作用机制研究进展[J]. 中国药物警戒, 2011, 8(8): 492-494.
[6]	铁常乐, 王传跃. 老年期与非老年期抑郁症患者用药情况对比研究[J]. 中国药物警戒, 2010, 7(7): 400-402.